Hormone modulation: a novel therapeutic approach for women with severe mental illness

References

• Riecher-Rossler A, Hafner H. Schizophrenia and oestrogens: is there an association?. Eur Arch Psychiatry Clin Neurosci 1993; 242: 323–328
   PubMed Web of Science ®Google Scholar
• Angermeyer MC, Kuhn L. Gender differences in age at onset of schizophrenia. An overview. Eur Arch Psychiatry Neurol Sci 1988; 237: 351–364
   PubMedGoogle Scholar
• Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 1992; 20: 1–97
   PubMedGoogle Scholar
• Loffler W, Hafner H, Fatkenheuer B, et al. Validation of Danish case register diagnosis for schizophrenia. Acta Psychiatr Scand 1994; 90: 196–203
   PubMed Web of Science ®Google Scholar
• Hafner H an der Heiden W. Epidemiology of schizophrenia. Can J Psychiatry 1997; 42:139–151.
   PubMed Web of Science ®Google Scholar
• Seeman MV. Current outcome in schizophrenia: women vs men. Acta Psychiatr Scand 1986; 73: 609–617
   PubMed Web of Science ®Google Scholar
• Seeman MV. The role of estrogen in schizophrenia. J Psychiatry Neurosci 1996; 21: 123–127
   PubMed Web of Science ®Google Scholar
• Riecher-Rossler A, Hafner H, Dutsch-Strobel A, et al. Further evidence for a specific role of estradiol in schizophrenia?. Biol Psychiatry 1994; 36: 492–494
   PubMed Web of Science ®Google Scholar
• Bergemann N, Parzer P, Runnebaum B, Resch F, Mundt C. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol Med 2007; 37: 1427–1436
   PubMed Web of Science ®Google Scholar
• Behl C, Manthey D. Neuroprotective activities of estrogen: an update. J Neurocytol 2000; 29: 351–358
   PubMedGoogle Scholar
• Garcia-Segura LM, Azcoitia I, DonCarlos LL. Neuroprotection by estradiol. Prog Neurobiol 2001; 63: 29–60
   PubMed Web of Science ®Google Scholar
• McEwen BS. Estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol 2001; 91: 2785–2801
   PubMed Web of Science ®Google Scholar
• Cyr M, Calon F, Morissette M, Di Paolo T. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J Psychiatry Neurosci 2002; 27: 12–27
   PubMed Web of Science ®Google Scholar
• Behl C. Estrogen can protect neurons: modes of action. J Steroid Biochem Mol Biol 2002; 83: 195–197
   PubMed Web of Science ®Google Scholar
• Taber KH, Murphy DD, Blurton-Jones MM, Hurley RA. An update on estrogen: higher cognitive function, receptor mapping, neurotrophic effects. J Neuropsychiatry Clin Neurosci 2001; 13: 313–317
   PubMed Web of Science ®Google Scholar
• Ostlund H, Keller E, Hurd YL. Estrogen receptor gene expression in relation to neuropsychiatric disorders. Ann N Y Acad Sci 2003; 1007: 54–63
   PubMed Web of Science ®Google Scholar
• Kritzer MF, Kohama SG. Ovarian hormones differentially influence immunoreactivity for dopamine beta-hydroxylase, choline acetyltransferase, and serotonin in the dorsolateral prefrontal cortex of adult rhesus monkeys. J Comp Neurol 1999; 409: 438–451
   PubMed Web of Science ®Google Scholar
• Dluzen D, Horstink M. Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies. Endocrine 2003; 21: 67–75
   PubMed Web of Science ®Google Scholar
• Bethea CL, Lu NZ, Gundlah C, Streicher JM. Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 2002; 23: 41–100
   PubMed Web of Science ®Google Scholar
• Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 1996; 20: 247–252
   PubMed Web of Science ®Google Scholar
• Kulkarni J, Riedel A, de Castella AR, et al. A clinical trial of adjunctive oestrogen treatment in women with schizophrenia. Arch Womens Ment Health 2002; 5: 99–104
   PubMedGoogle Scholar
• Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm Res 1997; 48: 155–163
   PubMed Web of Science ®Google Scholar
• Yaffe K, Krueger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005; 162: 683–690
   PubMed Web of Science ®Google Scholar
• Goldstein JA. Danazol and the rapid-cycling patient. J Clin Psychiatry 1986; 47: 153–154
   PubMed Web of Science ®Google Scholar
• Thompson DS, Spanier CA, Vogel VG. The relationship between tamoxifen, estrogen, and depressive symptoms. Breast J 1999; 5: 375–382
   PubMedGoogle Scholar
• Horgan K, Cooke E, Hallett MB, Mansel RE. Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity. Biochem Pharmacol 1986; 35: 4463–4465
   PubMed Web of Science ®Google Scholar
• Manji HK, Lenox RH. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999; 46: 1328–1351
   PubMed Web of Science ®Google Scholar
• Kulkarni J, Garland KA, Scaffidi A, et al. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 2006; 31: 543–547
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–276
   PubMed Web of Science ®Google Scholar
• Altman EG, Hedeker DR, Janicak PG, Peterson JL, Davis JM. The Clinician-Administered Rating Scale for Mania (CARS-M): development, reliability, and validity. Biol Psychiatry 1994; 36: 124–134
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389
   PubMed Web of Science ®Google Scholar
• Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998; 20: 310–319
   PubMed Web of Science ®Google Scholar
• Kulkarni J, de Castella A, Thompson K. Assessment of menstrual cycle phase in women with schizophrenia. In: The VIth International Congress on Schizophrenia Research. Colorado Springs, Colorado, USA. Schizophr Res 1997; 14: 12
   Google Scholar
• Thompson K, de Castella A, Kulkarni J. Psychotic women can estimate menstrual cycle phase as well as controls. Schizophr Res 1997; 23: 185–186
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Nejatisafa AA, Amini H, et al. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1007–1012
   PubMed Web of Science ®Google Scholar
• Amin Z, Canli T, Epperson CN. Effect of estrogen–serotonin interactions on mood and cognition. Behav Cogn Neurosci Rev 2005; 4: 43–58
   PubMedGoogle Scholar
• Haskell SG, Richardson ED. The effect of raloxifene on cognitive function in postmenopausal women: a randomized clinical trial. Conn Med 2004; 68: 355–358
   PubMedGoogle Scholar
• Nickelsen T, Lufkin EG, Riggs BL, Cox DA, Crook TH. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 1999; 24: 115–128
   PubMed Web of Science ®Google Scholar
• Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 2000; 57: 95–97
   PubMed Web of Science ®Google Scholar
• Zarate CA, Jr, Singh JB, Carlson PJ, et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 2007; 9: 561–570
   PubMed Web of Science ®Google Scholar
• Einat H, Yuan P, Szabo ST, Dogra S, Manji HK. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 2007; 55: 123–131
   PubMed Web of Science ®Google Scholar
• Post RM. Comparative pharmacology of bipolar disorder and schizophrenia. Schizophr Res 1999; 39:153–158; discussion 163.
   PubMed Web of Science ®Google Scholar